US3690316A - Contraceptive cervical obturator - Google Patents

Contraceptive cervical obturator Download PDF

Info

Publication number
US3690316A
US3690316A US63866A US3690316DA US3690316A US 3690316 A US3690316 A US 3690316A US 63866 A US63866 A US 63866A US 3690316D A US3690316D A US 3690316DA US 3690316 A US3690316 A US 3690316A
Authority
US
United States
Prior art keywords
obturator
pastille
base
contraceptive
cervical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US63866A
Inventor
Renee-Marie Haller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prairial Ets
Original Assignee
Prairial Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prairial Ets filed Critical Prairial Ets
Application granted granted Critical
Publication of US3690316A publication Critical patent/US3690316A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Definitions

  • ABSTRACT A cervical obturator for contraceptive use, containing an active substance, constituted by a fusiform shaped pastille terminating at one of its ends in an enlarged base, exercising an effect of obturation and having appropriate dimensions.
  • the active substance is acetylsalicylic acid in powder.
  • the subject of the present invention is a cervical obturator for use as a contraceptive, containing an active substance, characterized in that it is constituted by a pastille presenting a fusiform part, terminating at one of its ends in an enlarged base, acting as an obturator and having the appropriate dimensions.
  • FIG. 1 is a longitudinal view of the pastille.
  • FIG. 2 is a side view of the pastille.
  • FIG. 3 is a top view of the base of the pastille.
  • the cervical obturator comprises a fusiforrn part 1 terminating in a point at one end (the summit of the pastille), and at the other end, after a slight narrowing 2 (neck of the pastille) in an enlarged base 3.
  • the fusiform part has a length a of 2.3'centimeters. It is rounded off and bulging at the sides, having a maximum width b of 0.6 centimeter in the zone of the greatest bulge and at the level of the neck 2 a minimum width c of 0.3 centimeter.
  • This fusiforrn part seen in side view, as shown in FIG. 2, is flat and presents a plane surface of uniform thickness e of 0.2 centimeter.
  • the base 3 appears in plan view, as illustrated in FIG. 3, in the form of a small rectangle, with straight edges, transversally elongated and flattened from front to the rear; the thickness e is 00.4 centimeter and the length d varies from 0.5 to 1.5 centimeter according to the opening of the orifice of the neck of the uterus.
  • the height a' of this base is 0.2 centimeter, with the result that the total height of the cervical obturator, i.e. the height a of the fusifonn part added to the height a' of the base, is equal to 2.5 centimeters.
  • Such an obturator is placed in the neck of the uterus, the fusiform part 1 being directed towards the internal orifice of the neck of the uterus, while the base comes to obturate the external orifice of the neck.
  • the barrel shape of the pastille and its flattened surface fits entirely the form of the neck.
  • the obturators are manufactured by giving well determined dimensions to the base corresponding to the opening of the external orifice of the neck of the uterus.
  • the length d of the base is 0.5 centimeter for obturators meant for nullipara subjects, 1 centimeter for obturators meant for primipara subjects, and 1.5 centimeter for obturators meant for multipara subjects.
  • the fitting is thus perfectly occlusive.
  • the substance constituting the obturator could be an active contraceptive material of the type known, mixed with excipients.
  • the pastille once introduced into the neck of the uterus, acts by virtue of its constituting material, which dissolves in situ, as well as by the effect of obturation exercised by the base 3 of this pastille.
  • the material constituting the obturator could be an acid material, in the form of a powder, which is compressed in a mould, giving it the form of the obturator.
  • This material could notably be the acetylsalicylic acid, which offers the advantage of durable local action attaining a duration of 8 to 10 hours, and the advantage of its absolute harrnlessness for the cervical mucous membrane.
  • the concentration will be 0.50 of the acetylsalicylic acid, thus letting maintain in situ a pH of 4.5.
  • the cervical obturator described above thus offers a double advantage of contraception protection, mechanical, due to its base and spermicidal, due to its active acid product.
  • a cervical obturator for contraceptive purposes comprising a compressed acid powder with spermicidal properties and having a widened base exerting an obturating effect, characterized in that it is entirely composed of said powder and in that said powder is compressed in the form of a tablet having a fusiform appearance, said powder intended to be in direct contact with the human body and dissolving upon use.
  • Cervical obturator according to claim 1 characterized in that the powder is acetylsalicylic acid.

Abstract

A cervical obturator for contraceptive use, containing an active substance, constituted by a fusiform shaped pastille terminating at one of its ends in an enlarged base, exercising an effect of obturation and having appropriate dimensions. The active substance is acetylsalicylic acid in powder.

Description

United States Patent Haller 1 Sept. 12, 1972 [54] CONTRACEPTIVE CERVICAL OBTURATOR [72] Inventor: Renee-Marie Haller, Rouen, France [73] Assignee: Etablissement Prairial,
Liechlenstein [22] Filed: Aug. 14, 1970 [21] Appl. No.: 63,866
Vaduz,
[30] Foreign Application Priority Data Sept. 2, 1969 Switzerland ..13263/69 [52] US. Cl. ..128/l30, 128/271, 128/131 [51] Int. Cl ..A61f5/46, A6lf 15/00 [58] Field of Search ..l28/271, 260, 127, 130,131;
[56] References Cited UNITED STATES PATENTS 1,348,728 8/1920 Martocci-Pisculli ..l28/260 Primary ExaminerRichard A. Gaudet Assistant Examiner.l. C. McGowan Attorney-Emory L. Grofi' and Emory L. Groff, Jr.
[5 7] ABSTRACT A cervical obturator for contraceptive use, containing an active substance, constituted by a fusiform shaped pastille terminating at one of its ends in an enlarged base, exercising an effect of obturation and having appropriate dimensions. The active substance is acetylsalicylic acid in powder.
2 Claims, 3 Drawing Figures l g i l PATENTED SEP \2 1912 INVENTOR Pave: 4%4/8/5 HALLER BY W ATTORNEY CONTRACEPTIVE CERVICAL OBTURATOR The subject of the present invention is a cervical obturator for use as a contraceptive, containing an active substance, characterized in that it is constituted by a pastille presenting a fusiform part, terminating at one of its ends in an enlarged base, acting as an obturator and having the appropriate dimensions.
The attached drawing illustrates, schematically and by way of example, one embodiment of the invention.
FIG. 1 is a longitudinal view of the pastille.
FIG. 2 is a side view of the pastille.
FIG. 3 is a top view of the base of the pastille.
The cervical obturator comprises a fusiforrn part 1 terminating in a point at one end (the summit of the pastille), and at the other end, after a slight narrowing 2 (neck of the pastille) in an enlarged base 3.
The fusiform part has a length a of 2.3'centimeters. It is rounded off and bulging at the sides, having a maximum width b of 0.6 centimeter in the zone of the greatest bulge and at the level of the neck 2 a minimum width c of 0.3 centimeter.
This fusiforrn part, seen in side view, as shown in FIG. 2, is flat and presents a plane surface of uniform thickness e of 0.2 centimeter.
The base 3 appears in plan view, as illustrated in FIG. 3, in the form of a small rectangle, with straight edges, transversally elongated and flattened from front to the rear; the thickness e is 00.4 centimeter and the length d varies from 0.5 to 1.5 centimeter according to the opening of the orifice of the neck of the uterus. The height a' of this base is 0.2 centimeter, with the result that the total height of the cervical obturator, i.e. the height a of the fusifonn part added to the height a' of the base, is equal to 2.5 centimeters.
Such an obturator is placed in the neck of the uterus, the fusiform part 1 being directed towards the internal orifice of the neck of the uterus, while the base comes to obturate the external orifice of the neck. The barrel shape of the pastille and its flattened surface fits entirely the form of the neck.
The obturators are manufactured by giving well determined dimensions to the base corresponding to the opening of the external orifice of the neck of the uterus. For example, the length d of the base is 0.5 centimeter for obturators meant for nullipara subjects, 1 centimeter for obturators meant for primipara subjects, and 1.5 centimeter for obturators meant for multipara subjects. The fitting is thus perfectly occlusive.
The substance constituting the obturator could be an active contraceptive material of the type known, mixed with excipients.
The pastille, once introduced into the neck of the uterus, acts by virtue of its constituting material, which dissolves in situ, as well as by the effect of obturation exercised by the base 3 of this pastille.
As an interesting detail, the material constituting the obturator could be an acid material, in the form of a powder, which is compressed in a mould, giving it the form of the obturator. This material could notably be the acetylsalicylic acid, which offers the advantage of durable local action attaining a duration of 8 to 10 hours, and the advantage of its absolute harrnlessness for the cervical mucous membrane. The concentration will be 0.50 of the acetylsalicylic acid, thus letting maintain in situ a pH of 4.5.
The cervical obturator described above, thus offers a double advantage of contraception protection, mechanical, due to its base and spermicidal, due to its active acid product.
I claim:
1. A cervical obturator for contraceptive purposes comprising a compressed acid powder with spermicidal properties and having a widened base exerting an obturating effect, characterized in that it is entirely composed of said powder and in that said powder is compressed in the form of a tablet having a fusiform appearance, said powder intended to be in direct contact with the human body and dissolving upon use.
2. Cervical obturator according to claim 1, characterized in that the powder is acetylsalicylic acid.

Claims (1)

  1. 2. Cervical obturator according to claim 1, characterized in that the powder is acetylsalicylic acid.
US63866A 1969-09-02 1970-08-14 Contraceptive cervical obturator Expired - Lifetime US3690316A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1326369A CH507003A (en) 1969-09-02 1969-09-02 Birth control cervico-obturator

Publications (1)

Publication Number Publication Date
US3690316A true US3690316A (en) 1972-09-12

Family

ID=4390857

Family Applications (1)

Application Number Title Priority Date Filing Date
US63866A Expired - Lifetime US3690316A (en) 1969-09-02 1970-08-14 Contraceptive cervical obturator

Country Status (7)

Country Link
US (1) US3690316A (en)
BE (1) BE783135Q (en)
CH (1) CH507003A (en)
DE (1) DE2044401A1 (en)
ES (1) ES189913Y (en)
FR (1) FR2060602A5 (en)
GB (1) GB1268146A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3938517A (en) * 1975-03-14 1976-02-17 Anderson Carsten D Teat cautery bullet
US4004582A (en) * 1975-10-28 1977-01-25 Nakamura Robert M Intracervical contraceptive device
US4432758A (en) * 1982-08-30 1984-02-21 Finegold Aaron N Urethral anesthetic devices
US4460360A (en) * 1982-08-30 1984-07-17 Finegold Aaron N Urethral anesthetic devices
US4505711A (en) * 1981-06-24 1985-03-19 May & Baker Limited Deposit device for delivering biologically active substances to the digestive tract and method of using same
US4509504A (en) * 1978-01-18 1985-04-09 Medline Ab Occlusion of body channels
US20170266423A1 (en) * 2014-05-26 2017-09-21 Urobrain Gmbh Medicament carrier for the treatment and prevention of pathological conditions in the urogenital region

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1348728A (en) * 1919-10-08 1920-08-03 Martocci-Pisculli Leon Medicated pessary
US2832343A (en) * 1955-04-12 1958-04-29 Mose Clara Emilie Marie Dilators
CA578887A (en) * 1959-07-07 W. Millar Gerald Intravaginal obturating device
US2918404A (en) * 1956-07-30 1959-12-22 Ortho Pharma Corp Solid compressed amino acid spermicidal vehicle
US2928769A (en) * 1957-07-22 1960-03-15 Strong Cobb And Company Inc Production of controlled release medicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA578887A (en) * 1959-07-07 W. Millar Gerald Intravaginal obturating device
US1348728A (en) * 1919-10-08 1920-08-03 Martocci-Pisculli Leon Medicated pessary
US2832343A (en) * 1955-04-12 1958-04-29 Mose Clara Emilie Marie Dilators
US2918404A (en) * 1956-07-30 1959-12-22 Ortho Pharma Corp Solid compressed amino acid spermicidal vehicle
US2928769A (en) * 1957-07-22 1960-03-15 Strong Cobb And Company Inc Production of controlled release medicaments

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3938517A (en) * 1975-03-14 1976-02-17 Anderson Carsten D Teat cautery bullet
US4004582A (en) * 1975-10-28 1977-01-25 Nakamura Robert M Intracervical contraceptive device
US4509504A (en) * 1978-01-18 1985-04-09 Medline Ab Occlusion of body channels
US4505711A (en) * 1981-06-24 1985-03-19 May & Baker Limited Deposit device for delivering biologically active substances to the digestive tract and method of using same
US4432758A (en) * 1982-08-30 1984-02-21 Finegold Aaron N Urethral anesthetic devices
US4460360A (en) * 1982-08-30 1984-07-17 Finegold Aaron N Urethral anesthetic devices
US20170266423A1 (en) * 2014-05-26 2017-09-21 Urobrain Gmbh Medicament carrier for the treatment and prevention of pathological conditions in the urogenital region

Also Published As

Publication number Publication date
GB1268146A (en) 1972-03-22
FR2060602A5 (en) 1971-06-18
BE783135Q (en) 1972-09-01
DE2044401A1 (en) 1971-03-11
ES189913U (en) 1974-05-16
ES189913Y (en) 1974-11-01
CH507003A (en) 1971-05-15

Similar Documents

Publication Publication Date Title
Coutinho et al. The contractile response of the human uterus, fallopian tubes, and ovary to prostaglandins in vivo
US3789838A (en) Force transmitting intrauterine device
Calder et al. Prostaglandins and the unfavourable cervix
US3690316A (en) Contraceptive cervical obturator
US3683906A (en) Shielded intrauterine device
Doyle et al. Preliminary studies on the effect of hormone-releasing intrauterine devices
US3306286A (en) Intrauterine device
Blechner et al. Blood flow to the human uterus during maternal metabolic acidosis
US3323520A (en) Intrauterine pessary
US3352299A (en) Cyologic pan-scraper
Karim Intrauterine prostaglandins for outpatient termination of very early pregnancy
Corson et al. Cervical rupture following induced abortion
Timonen et al. Hysterographic studies with the copper T (TCu 200) in situ
Mohammad-Yari et al. Comparing the effects of vaginal misoprostol and oxytocin in successful induction of labor
RU2138229C1 (en) Pessary
US3675647A (en) Intrauterine contraceptive device
Hingorani et al. Early post-partum intrauterine contraceptive device insertions
Dolan et al. Forane increases bleeding in therapeutic suction abortion
Toppozada et al. Prostaglandin administration for induction of mid-trimester abortion in complicated pregnancies
Libenzon et al. Contractile activity of the uterus following intrauterine introduction of a polymer
Mirkov et al. Contraception in female heart patients
Lebech et al. A description of the intrauterine device, polygon (antigon)
Guiloff et al. Effect of oxytocin on the contractility of the human oviduct in vivo
SU130415A1 (en) Birth control pills
Lippes et al. The loop, age 7 with five significant years of observation